Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Alpha-L-fucosidase 2 (FUCA2) is a secreted enzyme responsible for the removal of terminal fucose residues from glycoproteins and other glycoconjugates, playing a critical role in modulating extracellular glycan structures[1][3]. It is a member of the glycosyl hydrolase 29 family and catalyzes the hydrolysis of alpha-1,6-linked fucose joined to the reducing-end N-acetylglucosamine of carbohydrate moieties. The enzyme is essential for microbial adhesion, such as facilitating Helicobacter pylori binding in gastric tissues. FUCA2 is also upregulated in several cancers (correlating with poor prognosis and immunosuppression), linked to cardiovascular dysfunctions, and participates in immune cell signaling[1][3]. Its expression can be modulated by cytokines like interferon-gamma, suggesting a broader role in immune response and disease pathogenesis[1][3].
Enzymatic hydrolysis of terminal alpha-1,6-linked fucose residues from glycoproteins and glycoconjugates[1][3]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Alpha-L-fucosidase 2 (FUCA2).